Additionally, randomized placebo-controlled, double-masked clinical trials of salsalate, IL1Ra, and anti-TNF-α are being adapted to investigate whether these anti-inflammatory approaches change disease risk in obesity, type 2 diabetes, and atherosclerotic cardiovascular disease [60]. The gene discussed is TNF; the disease is Obesity.